- Home
- AKA vs SGMO Comparison
AKA vs SGMO Comparison
Compare AKA & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | SGMO |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 141.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AKA | SGMO |
|---|---|---|
| Price | $9.82 | $0.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.33 | $5.75 |
| AVG Volume (30 Days) | 1.4K | ★ 4.1M |
| Earning Date | 06-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $36,567,000.00 |
| Revenue This Year | $5.83 | $4.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 4.44 | ★ 88.60 |
| 52 Week Low | $7.00 | $0.35 |
| 52 Week High | $16.90 | $1.05 |
Technical Indicators
Market Signals| Indicator | AKA | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 50.19 |
| Support Level | $9.31 | $0.36 |
| Resistance Level | $12.08 | $0.56 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 17.30 | 28.31 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.